The Project Sleep Podcast: Narcolepsy, Immunology & Neurology
Meet Our Episode Guest
Dr. Emmanuel Mignot, MD, PhD is the Craig Reynolds Professor of Sleep Medicine in the Department of Psychiatry and Behavioral Sciences at Stanford University. He is also the Director of the Stanford Center for Narcolepsy. Dr. Mignot is recognized as having discovered the cause of narcolepsy.
Dr. Mignot received his M.D. and Ph.D. (molecular pharmacology) from Paris V and VI University respectively. He practiced medicine and Psychiatry in France for several years before serving as a visiting scholar at the Stanford Sleep Disorders Clinic and Research Center. Dr. Mignot has received numerous awards for his work and is a member of both the National Academies of Sciences and Medicine.
This episode was recorded in April 2020 when the COVID-19 pandemic was still very new. Even so, this discussion remains timely and important as we continue to learn so much from the fascinating frontiers of immunology and neuroscience. Watch the full broadcast here.
More with Dr. Mignot
Drs. Emmanuel Mignot & Masashi Yanagisawa Win the 2023 Breakthrough Prize
Dr. Emmanuel Mignot and Dr. Masashi Yanagisawa won the 2023 Breakthrough Prize in Life Sciences for discovering the cause of narcolepsy. Narcolepsy is a chronic neurological condition that impairs the brain’s ability to regulate the sleep-wake cycle. Learn more about the 2023 Breakthrough Prize.
Narcolepsy Video with Dr. Mignot, Julie Flygare & Watson
In September 2018, Julie Flygare, J.D., President & CEO of Project Sleep, hosted an “Ask Me Anything” with special guests, Emmanuel Mignot, and Watson, a chihuahua with narcolepsy. Watch the interview with Dr. Mignot and Watson on Facebook.
Narcolepsy in 2020: World Narcolepsy Day Expert Panel
In Project Sleep’s feature event for World Narcolepsy Day 2020, a panel of leading narcolepsy clinicians and researchers spoke to our President & CEO, Julie Flygare about narcolepsy research progress and novel drug development underway. In this video, Dr. Mignot kicked off the broadcast sharing his enthusiasm about the novel orexin/hypocretin agonist treatment under development and in clinical trials across the United States and a few other places internationally. See more videos from this panel.